Cargando…

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis

OBJECTIVE: Immunological studies have demonstrated a plethora of beneficial effects of dimethyl fumarate (DMF) on various cell types. However, the cellular and molecular targets are incompletely understood and response markers are scarce. Here, we focus on the relation between nuclear factor (erythr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hammer, Anna, Waschbisch, Anne, Kuhbandner, Kristina, Bayas, Antonios, Lee, De‐Hyung, Duscha, Alexander, Haghikia, Aiden, Gold, Ralf, Linker, Ralf A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989754/ https://www.ncbi.nlm.nih.gov/pubmed/29928650 http://dx.doi.org/10.1002/acn3.553

Ejemplares similares

Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells
por: Hammer, Anna, et al.
Publicado: (2017)

Propionic acid beneficially modifies osteoporosis biomarkers in patients with multiple sclerosis
por: Duscha, Alexander, et al.
Publicado: (2022)

Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
por: Ellrichmann, Gisa, et al.
Publicado: (2018)

Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis
por: Vohl, Katja, et al.
Publicado: (2019)

Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters
por: Lee, De-Hyung, et al.
Publicado: (2012)

Multiple sclerosis and nutrition: back to the future?
por: Gold, Ralf, et al.
Publicado: (2020)

Propionic Acid Rescues High-Fat Diet Enhanced Immunopathology in Autoimmunity via Effects on Th17 Responses
por: Haase, Stefanie, et al.
Publicado: (2021)

Vascular pathology in multiple sclerosis: mind boosting or myth busting?
por: Waschbisch, Anne, et al.
Publicado: (2011)

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient
por: Kogel, Ann-Kathrin, et al.
Publicado: (2021)

Western lifestyle and immunopathology of multiple sclerosis
por: Matveeva, Olga, et al.
Publicado: (2018)

Induction of Regulatory Properties in the Intestinal Immune System by Dimethyl Fumarate in Lewis Rat Experimental Autoimmune Neuritis
por: Pitarokoili, Kalliopi, et al.
Publicado: (2019)

Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
por: Moharregh-Khiabani, D, et al.
Publicado: (2009)

Glial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis
por: Metz, Imke, et al.
Publicado: (2015)

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
por: Lee, De-Hyung, et al.
Publicado: (2013)

Environmental factors in autoimmune diseases and their role in multiple sclerosis
por: Jörg, Stefanie, et al.
Publicado: (2016)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation
por: Hammer, Anna, et al.
Publicado: (2017)

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
por: Wurm, Hannah, et al.
Publicado: (2020)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method
por: Gold, Ralf, et al.
Publicado: (2023)

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
por: Viglietta, Vissia, et al.
Publicado: (2015)

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
por: Kappos, L, et al.
Publicado: (2015)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)

Elevated levels of miR-181c and miR-633 in the CSF of patients with MS: A validation study
por: Kramer, Svenja, et al.
Publicado: (2019)

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE
por: Gold, Ralf, et al.
Publicado: (2020)

Visual Search as a Tool for a Quick and Reliable Assessment of Cognitive Functions in Patients with Multiple Sclerosis
por: Utz, Kathrin S., et al.
Publicado: (2013)

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM
por: Fox, Robert J., et al.
Publicado: (2017)

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
por: Gold, Ralf, et al.
Publicado: (2021)

Functional and structural readouts for early detection of retinal involvement in multiple sclerosis
por: Al-Nosairy, Khaldoon O., et al.
Publicado: (2023)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cvvt9bnj27vq98h53qe2ifnbgq